PRMT5 inhibitor

preclinical (MTAP-deleted cancers)

from fragment-based design + SBDD

J. Med. Chem.

Mirati Therapeutics

PRMT5 inhibitor - Mirati Therapeutics

MRTX1719 is PRMT5-MTA complex inhibitor for the treatment of MTAP-deleted cancers currently in IND-enabling studies. PRMT5 is a target of active interest with several molecules recently highlighted here. Inhibition…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: